Myo-Inositol + D-Chiro-Inositol + Folic Acid Sachets

Polycystic ovary syndrome (PCOS) affects 8–13% of women globally, characterised by hyperandrogenism, chronic anovulation, and insulin resistance. The two primary inositol isomers — myo-inositol and D-chiro-inositol — function as intracellular insulin second messengers and have emerged as evidence-based interventions for PCOS-associated insulin resistance and ovulatory dysfunction. MSVD Labs’ Myo-Inositol + D-Chiro-Inositol + Folic Acid Sachets are formulated at the physiologically optimal 40:1 myo-inositol to D-chiro-inositol ratio — the same ratio found in healthy human follicular fluid. This 40:1 ratio is based on the research of Professor Enrico Papaleo and subsequent corroborating clinical trials, which established that this specific ratio restored follicular fluid inositol composition, improved oocyte quality, reduced circulating androgens, and restored menstrual regularity in women with PCOS. Studies using higher D-chiro-inositol ratios paradoxically worsened oocyte quality, confirming the critical importance of the ratio over total dose. Folic acid at 400mcg is co-included as an essential cofactor for cell division, DNA methylation, and neural tube development — particularly important given that women with PCOS have elevated miscarriage rates and frequently require fertility support. Manufactured under WHO-GMP and ISO 9001:2015 certification at MSVD Labs’ Surat, Gujarat facility. The sachet format ensures accurate dosing and improved patient compliance in clinical settings. Sugar-free formulation suitable for insulin-resistant patients. Available in 30-sachet and 60-sachet box configurations. Custom co-formulations with vitamin D3, chromium, and N-acetyl cysteine available for B2B buyers. FSSAI-compliant with full export documentation. Trade pricing available on enquiry.